GlobeNewswire Inc.··NaSanuwave Posts Modest Q1 Growth Ahead of May Earnings Call
$SNWV expects Q1 revenue of $9.6-$9.7M, up 3-4% YoY. Company to discuss results May 13.
SNWVrevenue growthregenerative medicine
regenerative medicine
19 articlesGlobeNewswire Inc.··NaGlobeNewswire Inc.··DelveinsightStem Cell Therapy Market Surges to $58.5B by 2034 on Tech, Regulation Tailwinds
Global stem cell therapy market projected to grow from $21.9B in 2025 to $58.5B by 2034 at 11% CAGR, driven by technological advances and favorable regulations.
TAKVCELSMDPYclinical trialsregenerative medicine
GlobeNewswire Inc.··NaMesoblast Hits Recruitment Milestone in Pivotal Back Pain Trial
Mesoblast completes recruitment of 300+ patients in pivotal Phase 3 trial for chronic back pain therapy, targeting mid-2027 results and Q3 2027 FDA filing.
MESOPhase 3 clinical trialFDA approval
GlobeNewswire Inc.··Mordor IntelligenceTissue Engineering Market Poised to Nearly Double to $27.6B by 2031
Tissue engineering market projected to grow from $15.01B to $27.59B by 2031 at 12.95% CAGR, driven by regenerative medicine advances and 3D bioprinting innovation.
MDTSNNZBHORGOIARTregenerative medicinebiomaterials
GlobeNewswire Inc.··NaSanuwave Health Posts Modest Q1 2026 Growth Amid Reimbursement Headwinds
Sanuwave Health reports Q1 2026 revenues of $9.6–$9.7M, up 3-4% YoY, citing reimbursement headwinds. CEO highlights strong Ultramist interest at SAWC conference.
SNWVregenerative medicinewound care
GlobeNewswire Inc.··NaOrganogenesis Wins Key Trial for Diabetic Ulcer Treatment, Bolstering PuraPly®AM Case
Organogenesis's PuraPly®AM met primary endpoint in diabetic ulcer trial with statistically significant 12-week wound closure, supporting future insurance coverage expansion.
ORGOregenerative medicinerandomized controlled trial
Benzinga··Usa News Group$578B Regenerative Medicine Market Faces Manufacturing Crisis as Avaí Bio Pioneers Cell Banking Solution
Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.
PRMEIOVAAVAIMDGLDNLIFDA approvalregenerative medicine
GlobeNewswire Inc.··NaSanuwave Posts Record $44.1M Revenue on UltraMist Momentum, Eyes 16-25% Growth in 2026
Sanuwave Health reported record 2025 revenues of $44.1M, up 35% YoY, driven by strong UltraMist system sales and improved margins.
SNWVrevenue growthregenerative medicine
Benzinga··Globe NewswireRelativity Acquisition Shareholders OK SPAC Merger with Stem Cell Pioneer Instinct Bio
Relativity Acquisition shareholders approve SPAC merger with stem cell company Instinct Bio Technical, enabling Nasdaq listing under $BIOT and $BIOTW expected within weeks.
ACQCSPAC mergerregenerative medicine
GlobeNewswire Inc.··NaRelativity Acquisition Corp. Shareholders Greenlight SPAC Merger with Instinct Bio
Relativity Acquisition Corp. shareholders approved merger with stem cell firm Instinct Bio Technical Company Inc. Combined entity to trade on Nasdaq as $BIOT and $BIOTW.
ACQCSPAC mergerregenerative medicine
Benzinga··Equity-Insider.ComAvaí Bio Advances Anti-Aging Therapy With Klotho Protein Cloning Milestone
Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.
VRTXCRSPAVAIALTregenerative medicinegene therapy
Benzinga··Equity-Insider.ComBiotech Breakthrough: Avaí Bio Moves Anti-Aging Protein Therapy Into Production
Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.
MESOMNKDLGVNAVAILCTXregenerative medicinecell therapy
Benzinga··PrnewswireCollPlant Biotechnologies Revamps Digital Presence to Showcase Collagen Pipeline
CollPlant Biotechnologies launches redesigned website showcasing plant-derived collagen technology, product pipeline, and investor resources to enhance market transparency and stakeholder engagement.
ABBVCLGNregenerative medicinedermal fillers
GlobeNewswire Inc.··Mordor IntelligenceOrthobiologics Market Set to Hit $9.5B by 2031 as Regenerative Medicine Surges
Global orthobiologics market projected to grow 43% to $9.52B by 2031, driven by rising osteoarthritis and regenerative therapy advancements.
JNJSYKMDTZBHBVS+1regenerative medicinestem cell therapy
GlobeNewswire Inc.··Biorestorative Therapies, Inc.BioRestorative Therapies to Showcase Regenerative Skincare Tech at Major NYC Wellness Event
BioRestorative Therapies will exhibit at Be+Well Beauty and Wellness Show in NYC (March 8-10, 2026) to advance its BioCosmeceutical platform commercialization.
BRTXclinical developmentregenerative medicine
Benzinga··PrnewswireCell Therapies Graduate to Mass Production as Market Eyes $8.2B Prize
Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.
MESOFATEFBLGLGVNbiotechclinical trials
GlobeNewswire Inc.··Mordor IntelligenceCord Blood Banking Market Poised for 47% Growth Through 2031
Cord blood banking market expected to grow 47% to $49.85B by 2031, driven by expanding stem cell therapies and regenerative medicine applications.
CCELRVTYcord blood bankingstem cell therapies
GlobeNewswire Inc.··NaBioStem Technologies to Showcase Perinatal Tissue Platform at TD Cowen Healthcare Conference
BioStem Technologies will present its perinatal tissue-based wound care platform at the TD Cowen Healthcare Conference on March 2, 2026, in Boston.
BSEMregenerative medicinemedical devices
GlobeNewswire Inc.··NaBioRestorative Closes $5M Equity Offering to Fund Stem Cell Pipeline
BioRestorative raised $5M through equity offering to advance stem cell therapies, including BRTX-100 for spine disease and metabolic disorder research.
BRTXclinical trialsregenerative medicine